Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Somatostatin Receptor 2 and 5 Expressions in Gastroenteropancreatic Neuroendocrine Tumors in Turkey

  • Yerci, Omer (Department of Pathology, Faculty of Medicine, Uludag University) ;
  • Sehitoglu, Ibrahim (Department of Pathology, Faculty of Medicine, Recep Tayyip Erdogan University) ;
  • Ugras, Nesrin (Department of Pathology, Faculty of Medicine, Uludag University) ;
  • Cubukcu, Erdem (Department of Medical Oncology, Faculty of Medicine, Uludag University) ;
  • Yuce, Suleyman (Department of Internal Medicine, Faculty of Medicine, Recep Tayyip Erdogan University) ;
  • Bedir, Recep (Department of Pathology, Faculty of Medicine, Recep Tayyip Erdogan University) ;
  • Cure, Erkan (Department of Internal Medicine, Faculty of Medicine, Recep Tayyip Erdogan University)
  • Published : 2015.06.03
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Gastroenteropancreatic neuroendocrine tumors (GNs) are slow growing and although their incidence has increased in recent years, they are relatively rarely seen. Somatostatin analogues are used in the treatment of GNs that express somatostatin receptor (SR). We aimed to investigate the expression of SR2 and SR5 in GNs. Materials and Methods: In this study the expression of SR2 and SR5 was investigated immunohistochemically in 49 cases (26 males, 23 females) diagnosed and graded with GN according to the World Health Organization classification 2010. Results: The percentage of SR2 staining was 91.0% in grade 1, 82.8% in grade 2 and 100% in grade 3. On the other hand, the percentage of SR5 staining was 81.8% % in grade 1, 60.0% in grade 2 and 0% in grade 3. According to the tumor localization, the percentages of SR2 expression were as follows: pancreas 85.7%, stomach 100%, small bowel 70%, appendix 85.7% and rectum 100%. The percentages of SR5 expression were: pancreas 61,9%, stomach 37.5%, small bowel 70%, appendix 71.5% and rectum 66.6%. There was a significant negative correlation between ki67 percentage and SR5 expression (r=-0.341, p=0.016). Conclusions: In this study, GNs were found to highly express SR2 and SR5. Although the expression of SR2 and SR5 changed according to tumor localization, the expression of SR2 was higher than the expression of SR5 in GN. There was a significant negative correlation between ki67 and SR5. Accordingly, SR5 may be a prognostic indicator of GN.

Keywords

References

  1. Akerstrom G, Hellman P (2007). Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab, 21, 87-109. https://doi.org/10.1016/j.beem.2006.12.004
  2. Bertherat J, Tenenbaum F, Perlemoine K, et al (2003). Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab, 88, 5353-60. https://doi.org/10.1210/jc.2002-021895
  3. Delaunoit T, Rubin J, Neczyporenko F, Erlichman C, Hobday TJ (2005). Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc, 80, 502-6. https://doi.org/10.4065/80.4.502
  4. Demirkan BH, Eriksson B (2012). Systemic treatment of neuroendocrine tumors with hepatic metastases. Turk J Gastroenterol, 23, 427-37. https://doi.org/10.4318/tjg.2012.0552
  5. de Sa SV, Correa-Giannella ML, Machado MC, et al (2006). Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas. Endocr Relat Cancer, 13, 69-78. https://doi.org/10.1677/erc.1.00962
  6. Guo RS, Shi PD, Zhou J, Chen YY (2013). Somatostatin receptors 3, 4 and 5 play important roles in gallbladder cancer. Asian Pac J Cancer Prev, 14, 4071-5. https://doi.org/10.7314/APJCP.2013.14.7.4071
  7. Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM (2008). Pancreatic endocrine neoplasms: Epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer, 15, 409-27. https://doi.org/10.1677/ERC-07-0221
  8. Iida S, Miki Y, Ono K, et al (2010). Novel classification based on immunohistochemistry combined with hierarchical clustering analysis in non-functioning neuroendocrine tumor patients. Cancer Sci, 101, 2278-85. https://doi.org/10.1111/j.1349-7006.2010.01657.x
  9. Kilickap S, Kaya Y, Yucel B, Tuncer E, Babacan NA, Elagoz S (2014). Higher Ki67 expression is associates with unfavorable prognostic factors and shorter survival in breast cancer. Asian Pac J Cancer Prev, 15, 1381-5. https://doi.org/10.7314/APJCP.2014.15.3.1381
  10. Kloppel G, Anlauf M (2005). Epidemiology, tumour biology and histopathological classification of neuroendocrine tumours of the gastrointestinal tract. Best Pract Res Clin Gastroenterol, 19, 507-17. https://doi.org/10.1016/j.bpg.2005.02.010
  11. Kloppel G, Rindi G, Anlauf M, Perren A, Komminoth P (2007). Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch, 451, 9-27. https://doi.org/10.1007/s00428-007-0461-0
  12. Koc EU, Ozgur T, Yerci O, Gurel S (2013). Somatostatin receptor 1 (SSTR1) and somatostatin receptor 5 (SSTR5) expression in hepatocellular carcinoma. Hepatogastroenterology, 60, 1693-7.
  13. Lamberts SW, de Herder WW, Hofland LJ (2002). Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab, 13, 451-7. https://doi.org/10.1016/S1043-2760(02)00667-7
  14. Liu SZ, Zhang F, Chang YX, et al (2013). Prognostic impact of cyclin D1, cyclin E and P53 on gastroenteropancreatic neuroendocrine tumours. Asian Pac J Cancer Prev, 14, 419-22. https://doi.org/10.7314/APJCP.2013.14.1.419
  15. Modlin IM, Oberg K, Chung DC, et al (2008). Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol, 9, 61-72. https://doi.org/10.1016/S1470-2045(07)70410-2
  16. Modlin IM, Moss SF, Oberg K, et al (2010). Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. Med J Aust, 193, 46-52.
  17. Nakayama Y, Wada R, Yajima N, Hakamada K, Yagihashi S (2010). Profiling of somatostatin receptor subtype expression by quantitative PCR and correlation with clinicopathological features in pancreatic endocrine tumors. Pancreas, 39, 1147-54. https://doi.org/10.1097/MPA.0b013e3181e78120
  18. Oberg K (2001). Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol, 12, 111-4. https://doi.org/10.1023/A:1012465801251
  19. Oberg K, Kvols L, Caplin M, et al (2004). Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol, 15, 966-73. https://doi.org/10.1093/annonc/mdh216
  20. Papotti M, Bongiovanni M, Volante M, et al (2002). Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch, 440, 461-75. https://doi.org/10.1007/s00428-002-0609-x
  21. Pisarek H, Pawlikowski M, Kunert-Radek J, Kubiak R, Winczyk K (2010). SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors. Folia Histochem Cytobiol, 48, 142-7.
  22. Rindi G, Arnold R, Bosman FT, et al (2010). Nomenclature and classification of neuroendocrine neoplasms of the digestive system, Eds Bosman FT, Carnerio F, Hruban RH, Theise ND, WHO classification of tumors of the digestive system. Fourth ed. WHO press, Lyon, pp. 13-4 .
  23. Sclafani F, Carnaghi C, Di Tommaso L, et al (2011). Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors. Tumori, 97, 620-8. https://doi.org/10.1177/030089161109700514
  24. Volante M, Brizzi MP, Faggiano A, et al (2007). Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol, 20, 1172-82. https://doi.org/10.1038/modpathol.3800954
  25. Yeniay L, Gurcu B, Unalp O, et al (2012). Prognostic value of somatostatin receptor-2 positivitiy in gastroenteropancreatic neuroendocrine tumors in reference to known prognostic factors. Turk J Gastroenterol, 23, 736-40. https://doi.org/10.4318/tjg.2012.0476
  26. Zamora V, Cabanne A, Salanova R, et al (2010). Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis, 42, 220-5. https://doi.org/10.1016/j.dld.2009.07.018
  27. Zeng YJ, Liu L, Wu H, et al (2013). Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine tumors: analysis from a single-institution. Asian Pac J Cancer Prev, 14, 5775-81. https://doi.org/10.7314/APJCP.2013.14.10.5775
  28. Zhao WY, Zhuang C, Xu J, et al (2014). Somatostatin receptors in gastrointestinal stromal tumors: new prognostic biomarker and potential therapeutic strategy. Am J Transl Res, 6, 831-40.
  29. Zhou G, Sinnett-Smith J, Liu SH, et al (2014). Front Physiol, 5, 226.
  30. Zhou Y, Jiang HG, Lu N, Lu BH, Chen ZH (2015). Expression of ki67 in papillary thyroid microcarcinoma and its clinical significance. Asian Pac J Cancer Prev, 16, 1605-8. https://doi.org/10.7314/APJCP.2015.16.4.1605

Cited by

  1. Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors vol.13, pp.3, 2017, https://doi.org/10.3892/ol.2017.5591
  2. Pasireotide in the treatment of neuroendocrine tumors: a review of the literature vol.25, pp.6, 2018, https://doi.org/10.1530/ERC-18-0010